{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anthrax",
    "query": {
      "intervention": "Anthrax"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 39,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anthrax&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T05:27:03.309Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03518125",
      "title": "BARDA Securing Anthrax Immunity For the Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "BioThrax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AV7909",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride injection USP, 0.9% (placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 305,
      "start_date": "2018-05-09",
      "completion_date": "2019-12-09",
      "has_results": true,
      "last_update_posted_date": "2020-07-21",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 4,
      "location_summary": "Lenexa, Kansas • Mt. Pleasant, South Carolina • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03518125"
    },
    {
      "nct_id": "NCT01794182",
      "title": "Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemic Stroke",
        "Malignant Edema"
      ],
      "interventions": [
        {
          "name": "Glyburide for Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Remedy Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 86,
      "start_date": "2013-06-13",
      "completion_date": "2016-04-04",
      "has_results": false,
      "last_update_posted_date": "2024-11-12",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Stanford, California • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01794182"
    },
    {
      "nct_id": "NCT00845650",
      "title": "Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "AIGIV 3.5 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gamunex 90 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AIGIV 7.0 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gamunex 180 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AIGIV 14.0 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gamunex 360 mg/kg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 129,
      "start_date": "2009-02",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00845650"
    },
    {
      "nct_id": "NCT01929226",
      "title": "Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inhalational Anthrax"
      ],
      "interventions": [
        {
          "name": "ETI-204",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Elusys Therapeutics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2013-07-09",
      "completion_date": "2013-11-29",
      "has_results": true,
      "last_update_posted_date": "2019-04-08",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01929226"
    },
    {
      "nct_id": "NCT02339155",
      "title": "Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infections, Bacterial"
      ],
      "interventions": [
        {
          "name": "AVA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Raxibacumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 573,
      "start_date": "2015-02-24",
      "completion_date": "2017-06-06",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 3,
      "location_summary": "Edgewater, Florida • Overland Park, Kansas • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Edgewater",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02339155"
    },
    {
      "nct_id": "NCT00448253",
      "title": "Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Symptoms of Inhalational Anthrax"
      ],
      "interventions": [
        {
          "name": "NP-015",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 92,
      "start_date": "2007-07",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448253"
    },
    {
      "nct_id": "NCT00063843",
      "title": "Anthrax-rPA: Safety, Tolerability, Immunogenicity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "Recombinant Protective Antigen, Anthrax Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": null,
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "2003-07",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00063843"
    },
    {
      "nct_id": "NCT00100724",
      "title": "Trial of rPA-102 Vaccine in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "rPA102",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "VaxGen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 480,
      "start_date": "2004-04",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2006-01-12",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 12,
      "location_summary": "Torrance, California • Atlanta, Georgia • Lexington, Kentucky + 9 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100724"
    },
    {
      "nct_id": "NCT01932242",
      "title": "Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inhalational Anthrax"
      ],
      "interventions": [
        {
          "name": "ETI-204",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Elusys Therapeutics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2013-07-23",
      "completion_date": "2014-04-19",
      "has_results": true,
      "last_update_posted_date": "2019-05-14",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 2,
      "location_summary": "Overland Park, Kansas • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01932242"
    },
    {
      "nct_id": "NCT01770743",
      "title": "A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "AV7909",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BioThrax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 168,
      "start_date": "2013-01",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-09-10T05:27:03.309Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Mt. Pleasant, South Carolina • New Braunfels, Texas + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01770743"
    }
  ]
}